Key result
Concurrent trastuzumab and left-sided radiotherapy did not significantly increase the rate of grade 1 LVEF dysfunction compared to radiotherapy alone (7.8% vs 4.1%, p=0.473).
Why the study?
Does concurrent trastuzumab increase cardiotoxicity in patients receiving left-sided adjuvant radiotherapy for breast cancer?
Cohort (n=137)
No
Does concurrent trastuzumab increase cardiotoxicity in patients receiving left-sided adjuvant radiotherapy for breast cancer?
Absolute Event Rate: 7.8% vs 4.1%
p-value: p=0.473
Concurrent trastuzumab and left-sided radiotherapy is well tolerated regarding cardiotoxicity in patients with normal baseline cardiac function, though trastuzumab and higher cardiac radiation doses increase the risk of acute LVEF dysfunction.
No takes yet. Share an insight, caveat, or question.
May permit concurrent use without excess acute LVEF concern in normal-function patients; leaves open confirmation in randomized trials.
Cao et al. (2015) conducted a cohort in Stage I-III left-sided breast cancer (n=137). Concurrent trastuzumab and left-sided radiotherapy vs. Left-sided radiotherapy alone was evaluated on Grade 1 LVEF dysfunction (p=0.473). Concurrent trastuzumab and left-sided radiotherapy did not significantly increase the rate of grade 1 LVEF dysfunction compared to radiotherapy alone (7.8% vs 4.1%, p=0.473).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: